Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Outcomes analysis of an alternative formulation of PEGylated liposomal doxorubicin in recurrent epithelial ovarian carcinoma during the drug shortage era.

Berger JL, Smith A, Zorn KK, Sukumvanich P, Olawaiye AB, Kelley J, Krivak TC.

Onco Targets Ther. 2014 Aug 8;7:1409-13. doi: 10.2147/OTT.S62881. eCollection 2014. Erratum in: Onco Targets Ther. 2015;8:593.

2.

Pegylated liposomal doxorubicin (Lipo-Dox) for platinum-resistant or refractory epithelial ovarian carcinoma: a Taiwanese gynecologic oncology group study with long-term follow-up.

Taiwanese Gynecologic Oncology Group, Chou HH, Wang KL, Chen CA, Wei LH, Lai CH, Hsieh CY, Yang YC, Twu NF, Chang TC, Yen MS.

Gynecol Oncol. 2006 Jun;101(3):423-8. Epub 2005 Dec 1.

PMID:
16325239
3.

Salvage chemotherapy in recurrent cervical cancer with biweekly pegylated liposomal Doxorubicin (lipo-dox).

Chen JR, Yang YC, Chen TC, Lai JC, Chang SJ, Chang CL, Wang KL.

Taiwan J Obstet Gynecol. 2008 Sep;47(3):322-6. doi: 10.1016/S1028-4559(08)60132-1.

4.
6.

Multiple sessions of liposomal doxorubicin delivery via focused ultrasound mediated blood-brain barrier disruption: a safety study.

Aryal M, Vykhodtseva N, Zhang YZ, McDannold N.

J Control Release. 2015 Apr 28;204:60-9. doi: 10.1016/j.jconrel.2015.02.033. Epub 2015 Feb 24.

7.

Nanodrug-enhanced radiofrequency tumor ablation: effect of micellar or liposomal carrier on drug delivery and treatment efficacy.

Moussa M, Goldberg SN, Kumar G, Sawant RR, Levchenko T, Torchilin VP, Ahmed M.

PLoS One. 2014 Aug 18;9(8):e102727. doi: 10.1371/journal.pone.0102727. eCollection 2014.

8.

Pegylated liposomal doxorubicin/carboplatin combination in ovarian cancer, progressing on single-agent pegylated liposomal doxorubicin.

Grenader T, Rosengarten O, Isacson R, Plotkin Y, Gabizon A.

World J Clin Oncol. 2012 Oct 10;3(10):137-41. doi: 10.5306/wjco.v3.i10.137.

9.

Phase II study of liposomal doxorubicin in advanced gynecologic cancers.

Israel VP, Garcia AA, Roman L, Muderspach L, Burnett A, Jeffers S, Muggia FM.

Gynecol Oncol. 2000 Aug;78(2):143-7.

PMID:
10926793
10.

A Phase II clinical trial of pegylated liposomal doxorubicin and carboplatin in Japanese patients with platinum-sensitive recurrent ovarian, fallopian tube or primary peritoneal cancer.

Nakanishi T, Aoki D, Watanabe Y, Ando Y, Tomotsugu N, Sato Y, Saito T.

Jpn J Clin Oncol. 2015 May;45(5):422-6. doi: 10.1093/jjco/hyv016. Epub 2015 Feb 10.

PMID:
25670764
11.
12.

Comparison of the therapeutic efficacy of 188Rhenium-liposomes and liposomal doxorubicin in a 4T1 murine orthotopic breast cancer model.

Liu CM, Lee WC, Yu CY, Lan KL, Chang CH, Ting G, Lee TW.

Oncol Rep. 2012 Mar;27(3):678-84. doi: 10.3892/or.2011.1557. Epub 2011 Nov 22.

PMID:
22109644
13.

Attenuated glial reaction in experimental proliferative vitreoretinopathy treated with liposomal doxorubicin.

Kuo HK, Chen YH, Wu PC, Wu YC, Huang F, Kuo CW, Lo LH, Shiea J.

Invest Ophthalmol Vis Sci. 2012 Jun 29;53(6):3167-74. doi: 10.1167/iovs.11-7972.

PMID:
22491400
14.

Focused ultrasound and interleukin-4 receptor-targeted liposomal doxorubicin for enhanced targeted drug delivery and antitumor effect in glioblastoma multiforme.

Yang FY, Wong TT, Teng MC, Liu RS, Lu M, Liang HF, Wei MC.

J Control Release. 2012 Jun 28;160(3):652-8. doi: 10.1016/j.jconrel.2012.02.023. Epub 2012 Mar 3.

PMID:
22405901
15.

Pegylated liposomal doxorubicin: tolerability and toxicity.

Goram AL, Richmond PL.

Pharmacotherapy. 2001 Jun;21(6):751-63.

PMID:
11401188
16.

Optimal chemotherapy treatment for women with recurrent ovarian cancer.

Fung-Kee-Fung M, Oliver T, Elit L, Oza A, Hirte HW, Bryson P.

Curr Oncol. 2007 Oct;14(5):195-208.

17.
19.

Phase 1b safety study of farletuzumab, carboplatin and pegylated liposomal doxorubicin in patients with platinum-sensitive epithelial ovarian cancer.

Kim KH, Jelovac D, Armstrong DK, Schwartz B, Weil SC, Schweizer C, Alvarez RD.

Gynecol Oncol. 2016 Feb;140(2):210-4. doi: 10.1016/j.ygyno.2015.11.031. Epub 2015 Nov 28.

20.

Effects of Doxorubicin Delivery Systems and Mild Hyperthermia on Tissue Penetration in 3D Cell Culture Models of Ovarian Cancer Residual Disease.

Eetezadi S, De Souza R, Vythilingam M, Lessa Cataldi R, Allen C.

Mol Pharm. 2015 Nov 2;12(11):3973-85. doi: 10.1021/acs.molpharmaceut.5b00426. Epub 2015 Oct 2.

PMID:
26394060

Supplemental Content

Support Center